PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing
Collaboration
SAN DIEGO, Feb. 9 /PRNewswire/ -- PacificGMP, the leader in single-use
bioprocessing for development and manufacturing for its client partners,
announced today that it has recently completed a collaboration with LigoCyte
Pharmaceuticals, Inc. Under the collaborative agreement, PacificGMP produced
master cell and baculovirus banks and will provide storage services under cGMP
(current good manufacturing practices) standards for LigoCyte's norovirus
vaccine program. Furthermore, PacificGMP conducted the services under an
accelerated timeline.
"We are pleased that LigoCyte chose PacificGMP to produce the master cell and
baculovirus banks that will be used to produce their next-generation,
intra-muscular norovirus vaccine candidate," said Leigh N. Pierce, President
of PacificGMP. "The timeline specified in this agreement further demonstrates
the time saving advantages of single-use technology as we were able to quickly
initiate this project in order to assist LigoCyte in maintaining its program
schedule."
"Through their diligent efforts, PacificGMP demonstrated their GMP proficiency
and allowed us to maintain our program timelines," said Bryan Steadman, Senior
Director of CMC Operations for LigoCyte. "We appreciate PacificGMP's
assistance in the development of our vaccine for norovirus infection, an
illness that afflicts an estimated 23 million individuals in the U.S.
annually, frequently resulting in serious medical consequences."
About PacificGMP
PacificGMP is a contract manufacturer and industry leader in single-use
technology for development and manufacturing of biologics. Single-use
technology eliminates the risk of cross-contamination, has fewer system
requirements and significantly reduces the time required to initiate
production. Benefits to clients include rapid project turnaround and the most
cost effective solution in the industry. PacificGMP partners with drug
developers by providing a range of cGMP and non-GMP services from cell line
optimization, early process design, development, purification and scale-up, to
preclinical and clinical manufacturing, aseptic filling, testing, analytical
services and regulatory support. More information can be found by visiting the
Company's web site at www.PacificGMP.com.
About LigoCyte Pharmaceuticals
LigoCyte Pharmaceuticals is a private biopharmaceutical company focused on the
development of innovative vaccine products based on the company's proprietary
virus-like particle platform technology. LigoCyte's lead candidate recently
completed a Phase I clinical trial. The vaccine is being developed for the
prevention of norovirus gastroenteritis, an illness that causes an estimated
64,000 hospitalizations and 900,000 clinical visits among children annually in
the U.S, according to the CDC. LigoCyte also has a novel influenza vaccine in
preclinical development that has, notably, demonstrated protection in ferrets
across multiple influenza subtypes with a single VLP antigen. Incorporated in
1998, LigoCyte has 45 employees and is located in Bozeman, Montana. Please
visit www.ligocyte.com for more information.
Contact:
PacificGMP
Gary Pierce
Chief Business Officer
858-550-4094
Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Leigh Pierce
http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271
SOURCE PacificGMP
Gary Pierce, Chief Business Officer of PacificGMP, +1-858-550-4094
